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Background
In Canada, Omalizumab is indicated for adults and ado-
lescents with moderate to severe persistent allergic
asthma, but not for pediatric use (<12 years of age). A 9
year-old boy with steroid dependent, allergic asthma,
multiple ICU admissions and severe back pain from
compression fractures was referred to our centre. IgE
was 1337 IU/ml. Skin prick testing showed multiple
positive reactions. Asthma treatment included inhaled
corticosteroids and frequent courses of oral prednisone.
Methods
After obtaining necessary approvals and informed con-
sents, Omalizumab treatment, 375mg every 2 weeks,
was initiated in September 2010. Serum cortisol levels,
bone density, spirometry, and PAQLQ were used to
monitor clinical response.
Results
After 11 months, the changes below were noted.
Conclusions
The patient improved and was off oral/inhaled corticos-
teroids with no asthma exacerbations. Spirometry,
serum cortisol, PAQLQ and bone density improved.
Prednisone treatment in young asthmatic children can
be associated with serious side effects. Omalizumab
therapy can permit steroid withdrawal and resolution of
side effects.
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Table 1
Daily Prednisone Daily ICS dose FEV1 Serum cortisol
‡ Bone density
* PAQLQ
†
2010
a 30 mg 800 mcg 1.46 L 12 nmol/L 0.626 g/cm
2 4.7
2011
b NIL 200 mcg 1.98 L 215 nmol/L 0.686 g/cm
2 7
a Pre Omalizumab treatment.
b Post Omalizumab treatment.
‡Morning results, range 185 – 624 nmol/L.
*Total hip.
†Pediatric asthma quality of life questionnaire with standardized activities: low 1 – 7 high.
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